Skip to main content

Oncolytic Adenovirus Ad5-DNX-2401

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

  • RegistryNCT03896568
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRecurrent Glioblastoma
  • SponsorM.D. Anderson Cancer Center
How Oncolytic Adenovirus Ad5-DNX-2401 worksNCT038965681 min

What the film says

Read the transcript

DNX-2401, a rebuilt cold virus that multiplies only in tumor cells, has been injected into glioblastomas for over a decade; a few patients lived for years. The limit is delivery: a needle reaches one spot; glioblastoma is everywhere.

The idea: hire cells that seek out tumors, and let them carry the virus in.

Mesenchymal stem cells from donor bone marrow home naturally to inflamed tissue, which describes a tumor exactly. They are loaded with the virus. Then, through a catheter threaded from the groin to the brain's arteries, they ride the tumor's own blood supply and unload the virus where they land.

This trial, at MD Anderson with Frederick Lang, is the first in people, finding a safe dose. Public record; not medical advice.

Sources behind this film

Show 1 more sources

The drug

What is being tested.

PRIMARY OBJECTIVES: I. To determine the maximal tolerated dose (MTD) of allogeneic bone marrow-derived human mesenchymal stem cells (BM-hMSCs) loaded with the oncolytic adenovirus DNX-2401 (BM-hMSCs-DNX2401) administered by intra-arterial injection (i.e., transfemoral endovascular intracranial injection) in patients with recurrent glioblastoma (GBM), IDH-mutant astrocytoma grade 4, gliosarcoma, or wild-type IDH-1 anaplastic astrocytoma. II.

To determine the local and systemic toxicity of allogeneic BM-hMSCs-DNX2401 administered by intra-arterial injection (i.e., transfemoral endovascular intracranial injection) in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma. III.

The study

How the trial runs.

This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Subjects must meet the following inclusion criteria to be eligible and enroll:
  • Subjects must be willing and able to provide informed consent, undergo and comply with all study assessments, and adhere to the protocol schedule.
  • Patients with recurrent malignant GBM or gliosarcoma will be eligible. Patients with recurrent anaplastic astrocytoma with wild-type IDH-1 gene will also be eligible if there is a significant enhancing mass on MRI (≥1.0 cm in diameter with upper limit of 5 cm maximal diameter) because their prognosis/behavior is similar to GBM. Subjects with an initial diagnosis of an IDH-mutant grade 2 or 3 astrocytoma are also eligible at recurrence if a biopsy at recurrence is determined to be IDH-mutant grade 4 astrocytoma, and there is a significant enhancing mass on MRI (≥1.0 cm in diameter with upper limit of 5 cm maximal diameter). A pathology report constitutes adequate documentation of histology for study inclusion.
  • Patients must show unequivocal evidence for tumor recurrence or progression by MRI scan after failing prior surgical resection, biopsy, chemotherapy or radiation. A baseline MRI must be performed within 24 days prior to registration. Biopsy is encouraged at the time of recurrence if it is unclear that there is recurrent tumor. However, biopsy is not required if the practicing physician thinks that there is adequate radiographic and clinical evidence for recurrence.
  • Male or female patients ≥ 18 years of age.
  • Patients must be able to undergo endovascular treatment based on Doppler studies showing ICA that is less than 50% occluded.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.